Related Experiment Video
Updated: May 9, 2026

Transmitochondrial Cybrid Generation Using Cancer Cell Lines
Published on: March 17, 2023
Decoding the metabolic cipher of dormant cancer cells: molecular mechanisms and therapeutic potentials
Yuao Qin1,2, Junling Zhang1,2, Yuyang Xiao3
1Hunan Key Laboratory of Oncotarget Gene, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, PR China.
Abstract:
Dormant cancer cells (DCCs) are non-proliferative cancer cells that enter cell cycle arrest in the G0-G1 phase and are recognized as a major cause of therapeutic resistance and cancer recurrence. In response to various intracellular and extracellular signals, DCCs undergo cellular reprogramming that confers drug resistance and enables them to evade immune surveillance. Once reactivated, these cells can resume proliferation, ultimately leading to tumor relapse. Metabolic reprogramming allows DCCs to adapt to the nutrient-deprived tumor microenvironment (TME), reduce energy consumption, and maintain redox homeostasis. Targeting these metabolic vulnerabilities provides promising opportunities to control recurrence and improve therapeutic outcomes. However, the metabolic reprogramming of DCCs is highly heterogeneous, which poses a major challenge for their complete eradication. In this review, we summarize the metabolic features of DCCs, describe the molecular mechanisms underlying metabolic reprogramming across distinct DCC subtypes, elucidate the interactive networks among distinct metabolic pathways, and discuss therapeutic strategies targeting metabolism of DCCs, with the goal of providing new insights into improving treatment efficacy and preventing recurrence.
Insights
Dormant cancer cells (DCCs) resist treatment and cause recurrence by altering their metabolism. Targeting these metabolic vulnerabilities offers new strategies to improve cancer therapy and prevent relapse.
Area of Science:
- Oncology
- Cancer Biology
- Metabolism
Background:
- Dormant cancer cells (DCCs) are non-proliferative cells in G0-G1 arrest.
- DCCs cause therapeutic resistance, immune evasion, and cancer recurrence.
- Metabolic reprogramming is crucial for DCC survival in nutrient-poor tumor microenvironments (TME).
Purpose of the Study:
- To review the metabolic characteristics of DCCs.
- To explore molecular mechanisms of DCC metabolic reprogramming.
- To discuss therapeutic strategies targeting DCC metabolism for improved treatment outcomes.
Main Methods:
- Literature review of studies on DCC metabolism.
- Analysis of molecular mechanisms driving metabolic adaptation in DCCs.
- Synthesis of information on metabolic pathways and their interactions in DCCs.
Main Results:
- DCCs exhibit significant metabolic reprogramming for survival and drug resistance.
- Metabolic heterogeneity among DCC subtypes presents a challenge for eradication.
- Targeting DCC metabolism shows promise for controlling recurrence.
Conclusions:
- Understanding DCC metabolic reprogramming is key to overcoming therapeutic resistance.
- Targeting metabolic vulnerabilities can prevent tumor relapse and improve patient outcomes.
- Further research into DCC metabolic heterogeneity is needed for effective treatment strategies.
Related Concept Videos
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
